Impact of current antiretroviral therapies on neuroAIDS

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 4, 2011, Pages 371-374

  Vivithanaporn, Pornpun ^a,b   Gill, M John ^c   Power, Christopher ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Mahidol University   (Thailand)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

antiretroviral drug induced neuropathy; cART; distal sensory polyneuropathy; HAART; HIV associated neurocognitive disorder; neuroactive HAART

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYTOKINE; DARUNAVIR; DIDANOSINE; EFAVIRENZ; ETRAVIRINE; INDINAVIR; INTEGRASE INHIBITOR; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL SUSCEPTIBILITY; BLOOD BRAIN BARRIER; BRAIN INFECTION; BRAIN INJURY; CD4 LYMPHOCYTE COUNT; CLINICAL EFFECTIVENESS; CONCENTRATION LOSS; CONFUSION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG PENETRATION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENCEPHALITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION COMPLICATION; INFECTION CONTROL; LEARNING DISORDER; MENTAL PERFORMANCE; MONOTHERAPY; NERVE CELL NECROSIS; NEUROLOGICAL COMPLICATION; NEUROPATHY; NEUROTOXICITY; NONHUMAN; POLYNEUROPATHY; PSYCHOMOTOR PERFORMANCE; PSYCHOPATHY; PSYCHOSIS; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SLEEP DISORDER; TREATMENT OUTCOME; VIRUS LOAD; VIRUS RESISTANCE;

AIDS DEMENTIA COMPLEX; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAIN; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; NERVOUS SYSTEM DISEASES;

EID: 79955086307     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.179     Document Type: Review

References (46)

1. Mocroft A, Ledergerber B, Katlama C et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362, 22-29 (2003). (Pubitemid 36835816)
2. McArthur JC, Hoover DR, Bacellar H et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology 43, 2245-2252 (1993). (Pubitemid 23346956)
3. So YT, Holtzman DM, Abrams DI, Olney RK. Peripheral neuropathy associated with acquired immunodeficiency syndrome. Prevalence and clinical features from a population-based survey. Arch. Neurol. 45, 945-948 (1988).
4. Vivithanaporn P, Heo G, Gamble J et al. Neurologic disease burden in treated HIV/ AIDS predicts survival: a population-based study. Neurology 75, 1150-1158 (2010).
5. Jones G, Power C. Regulation of neural cell survival by HIV-1 infection. Neurobiol. Dis. 21, 1-17 (2006). (Pubitemid 41817300)
6. Dore GJ, Correll PK, Li Y et al. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 13, 1249-1253 (1999). (Pubitemid 29361096)
7. Ives NJ, Gazzard BG, Easterbrook PJ. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART) in a London clinic. J. Infect. 42, 134-139 (2001). (Pubitemid 32631815)
8. Portegies P, de Gans J, Lange JM et al. Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. Br. Med. J. 299, 819-821 (1989). (Pubitemid 19235939)
9. Capparelli EV, Letendre SL, Ellis RJ et al. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. Antimicrob. Agents Chemother. 49, 2504-2506 (2005). (Pubitemid 40734489)
10. Anthonypillai C, Gibbs JE, Thomas SA. The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses. Cerebrospinal Fluid Res. 3, 1 (2006).
11. von Giesen HJ, Koller H, Theisen A, Arendt G. Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous system in HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. 29, 363-367 (2002). (Pubitemid 34288889)
12. Best BM, Koopmans PP, Letendre SL et al. Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J. Antimicrob. Chemother. 66(2) 354-357 (2010).
13. Taylor S, Pereira A. Penetration of HIV-1 protease inhibitors into CSF and semen. HIV Med. 1(Suppl. 2), 18-22 (2000).
14. Capparelli EV, Holland D, Okamoto C et al. Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS 19, 949-952 (2005). (Pubitemid 40834938)
15. Yilmaz A, Izadkhashti A, Price RW et al. Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. AIDS Res. Hum. Retroviruses 25, 457-461 (2009).
16. Yilmaz A, Stahle L, Hagberg L et al. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen. Scand. J. Infect. Dis. 36, 823-828 (2004). (Pubitemid 40074016)
17. Antinori A, Giancola ML, Grisetti S et al. Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients. AIDS 16, 1867-1876 (2002).
18. Cysique LA, Maruff P, Brew BJ. Antiretroviral therapy in HIV infection: are neurologically active drugs important? Arch. Neurol. 61, 1699-1704 (2004). (Pubitemid 39463428)
19. Cysique LA, Maruff P, Brew BJ. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology 66, 1447-1450 (2006). (Pubitemid 43739663)
20. Sacktor N, Tarwater PM, Skolasky RL et al. CSF antiretroviral drug penetrance and the treatment of HIV-associated psychomotor slowing. Neurology 57, 542-544 (2001).
21. Evers S, Rahmann A, Schwaag S et al. Prevention of AIDS dementia by HAART does not depend on cerebrospinal fluid drug penetrance. AIDS Res. Hum. Retroviruses 20, 483-491 (2004). (Pubitemid 38720961)
22. Giancola ML, Lorenzini P, Balestra P et al. Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 41, 332-337 (2006).
23. Letendre S, Marquie-Beck J, Capparelli E et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch. Neurol. 65, 65-70 (2008).
24. Letendre SL, Ellis RJ, Ances BM, McCutchan JA. Neurologic complications of HIV disease and their treatment. Top. HIV Med. 18, 45-55 (2010).
25. Canestri A, Lescure FX, Jaureguiberry S et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin. Infect. Dis. 50, 773-778 (2010).
26. Tozzi V, Balestra P, Salvatori MF et al. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J. Acquir. Immune Defic. Syndr. 52, 56-63 (2009).
27. Marra CM, Zhao Y, Clifford DB et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23, 1359-1366 (2009).
28. Yilmaz A, Verhofstede C, D'Avolio A et al. Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy. J. Acquir. Immune Defic. Syndr. DOI: 10.1097/QAI.0b013e3181f5b3d1 (2010) (Epub ahead of print).
29. Garvey L, Winston A, Sabin C. Do antiretroviral combination therapies with greater central nervous system (CNS) penetration prevent the development of CNS opportunistic diseases? Presented at: Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 16-19 February 2010.
30. Berger JR, Avison M. The blood brain barrier in HIV infection. Front. Biosci. 9, 2680-2685 (2004).
31. Power C, Kong PA, Crawford TO et al. Cerebral white matter changes in acquired immunodeficiency syndrome dementia: alterations of the blood-brain barrier. Ann. Neurol. 34, 339-350 (1993). (Pubitemid 23259602)
32. Luciano CA, Pardo CA, McArthur JC. Recent developments in the HIV neuropathies. Curr. Opin. Neurol. 16, 403-409 (2003). (Pubitemid 36688310)
33. Keswani SC, Chander B, Hasan C et al. FK506 is neuroprotective in a model of antiretroviral toxic neuropathy. Ann. Neurol. 53, 57-64 (2003). (Pubitemid 36083829)
34. Pettersen JA, Jones G, Worthington C et al. Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann. Neurol. 59, 816-824 (2006). (Pubitemid 43673159)
35. Ellis RJ, Marquie-Beck J, Delaney P et al. Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann. Neurol. 64, 566-572 (2008).
36. Maggiolo F. Efavirenz: a decade of clinical experience in the treatment of HIV. J. Antimicrob. Chemother. 64, 910-928 (2009).
37. Wise ME, Mistry K, Reid S. Drug points: neuropsychiatric complications of nevirapine treatment. Br. Med. J. 324, 879 (2002). (Pubitemid 34303940)
38. Allavena C, Le Moal G, Michau C, Chiffoleau A, Raffi F. Neuropsychiatric adverse events after switching from an antiretroviral regimen containing efavirenz without tenofovir to an efavirenz regimen containing tenofovir: a report of nine cases. Antivir. Ther. 11, 263-265 (2006).
39. Pistell PJ, Gupta S, Knight AG et al. Metabolic and neurologic consequences of chronic lopinavir/ritonavir administration to C57BL/6 mice. Antiviral Res. 88, 334-342 (2010).
40. Romao PR, Lemos JC, Moreira J et al. Anti-HIV drugs nevirapine and efavirenz affect anxiety-related behavior and cognitive performance in mice. Neurotox. Res. 19(1), 73-80 (2011).
41. Robertson KR, Su Z, Margolis DM et al. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology 74, 1260-1266 (2010).
42. Liner J, Meeker R, Robertson K. CNS toxicity of antiretroviral drugs. Presented at: Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 16-19 February 2010.
43. Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J. Neurovirol. 10, 350-357 (2004). (Pubitemid 40109622)
44. Sterne JA, May M, Costagliola D et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 373, 1352-1363 (2009).
45. Kmonickova E, Potmesil P, Holy A, Zidek Z. Purine P1 receptor-dependent immunostimulatory effects of antiviral acyclic analogues of adenine and 2,6-diaminopurine. Eur. J. Pharmacol. 530, 179-187 (2006). (Pubitemid 43037139)
46. Lagathu C, Eustace B, Prot M et al. Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir. Ther. 12, 489-500 (2007). (Pubitemid 47041147)